Partner Therapeutics
OverviewSuggest Edit
Partner Therapeutics is developing and commercializing cancer medicines and combination therapies.
| Type | Private | |
| Founded | 2017 | |
| HQ | Lexington, MA, US | Map |
| Website | partnertx.com | |
| Employee Ratings | More |
Recent NewsAll News
- BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients
- Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)
- Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease
- Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
Latest Updates
| Employees (est.) (Apr 2022) | 179 | |
| Cybersecurity rating | B | More |
Key People/Management at Partner Therapeutics
Bill McClements
Chief Financial and Operations Officer
Dave Carlson
Vice President Manufacturing
Sarah Kurz
Executive Vice President
Robert Mulroy
Chief Executive Officer
Debasish Roychowdhury
Chief Medical Officer
John McManus
Chief Business Officer
Partner Therapeutics Office Locations
Partner Therapeutics has offices in Lexington, Boston and Lynnwood
Lexington, MA, US (HQ)
19 Muzzey St
Boston, MA, US
1 Marina Park Drive #900
Lynnwood, WA, US
2625 162nd St SW
Partner Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2017 |
Partner Therapeutics total Funding | $60 m |
Partner Therapeutics latest funding size | $60 m |
Time since last funding | 4 years ago |
Partner Therapeutics investors | Adams Street Partners, Perceptive Advisors, MidCap Financial |
Partner Therapeutics's latest funding round in February 2018 was reported to be $60 m. In total, Partner Therapeutics has raised $60 m
Partner Therapeutics Cybersecurity Score
Partner Therapeutics Online and Social Media Presence
144 Twitter followers
Partner Therapeutics has 144 Twitter Followers. The number of followers has decreased 1% month over month and increased 2% quarter over quarter
Partner Therapeutics's Trends
Twitter Engagement Stats for @PartnerTx
125
Tweets
131
Following
144
Followers
5
Tweets last 30 days
3.8
Avg. likes per Tweet
100%
Tweets with engagement
Partner Therapeutics News and Updates
September 20, 2021
BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients
LEXINGTON, Mass., Sept. 20, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health...
April 29, 2021
Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)
LEXINGTON, Mass., April 29, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the SCOPE clinical trial, a randomized, placebo-controlled, double-blind phase 2 study of inhaled Leukine...
March 24, 2021
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease
LEXINGTON, Mass., March 24, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in...
March 03, 2021
Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
LEXINGTON, Mass., March 3, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has...
February 18, 2021
Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)
LEXINGTON, Mass., Feb. 18, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of Leukine (sargramostim, yeast-derived rhu GM-CSF) to improve survival in patients expoed to...
September 11, 2020
Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
LEXINGTON, Mass., Sept. 11, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA61411 being conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and led...
Partner Therapeutics Blogs
March 29, 2022
Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging
Pre-clinical study with recombinant murine GM-CSF reversed cognitive impairment in Dp16 model of Down syndrome and improved cognitive function in aged normal mice
The CU Anschutz Medical Campus team recently awarded a grant from the National Institutes of Health/National Institute on Aging to study …
August 17, 2021
“A Drug Before Its Time?” LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicity
Authors also highlight promising data in neurodegenerative diseases, fungal infection, and respiratory diseases including aPAP and COVID-19
Lexington, MA – August 17, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced today that Frontiers in Immunology published a systematic review of LE…
May 19, 2021
Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson’s Disease
Immune transformation after intermittent dosing with Leukine shows promise for Parkinson’s disease
LEXINGTON, MA – May 19, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT03790670) evaluatin…
March 24, 2021
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease
Patients with mild-to-moderate Alzheimer’s disease (AD) receiving Leukine experienced significant reversal of cognitive loss and biomarkers of disease progression while taking Leukine
Study shows Leukine safe and tolerable and concludes that the innate immune system is a viable target for therapeuti…
Partner Therapeutics Frequently Asked Questions
When was Partner Therapeutics founded?
Partner Therapeutics was founded in 2017.
Who are Partner Therapeutics key executives?
Partner Therapeutics's key executives are Bill McClements, Dave Carlson and Sarah Kurz.
How many employees does Partner Therapeutics have?
Partner Therapeutics has 179 employees.
Who are Partner Therapeutics competitors?
Competitors of Partner Therapeutics include Halozyme Therapeutics, Elea Laboratories and OncoTherapy Science.
Where is Partner Therapeutics headquarters?
Partner Therapeutics headquarters is located at 19 Muzzey St, Lexington.
Where are Partner Therapeutics offices?
Partner Therapeutics has offices in Lexington, Boston and Lynnwood.
How many offices does Partner Therapeutics have?
Partner Therapeutics has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies